The short version of GLP-1 receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-08 and is reviewed periodically as new material appears.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
== Burial methods == In many cultures, human corpses were usually buried in soil. The roots of burial as a practice reach back into the Middle Palaeolithic and coincide with the appearance of Homo neanderthalensis and Homo sapiens, in Europe and Africa respectively. As a result, burial grounds are found throughout the world. Through time, mounds of earth, temples, and caverns were used to store the dead bodies of ancestors. In modern times, the custom of burying dead people below ground, with a stone marker to indicate the burial place, is used in most cultures; although other means such as cremation are becoming more popular in the West (cremation is the norm in India and mandatory in big metropolitan areas of Japan). Some burial practices are heavily ritualized; others are simply practical.
== Signs and symptoms == Prediabetes typically has no distinct signs or symptoms except the sole sign of high blood sugar. People with prediabetes should monitor for signs and symptoms of type 2 diabetes such as increased thirst, increased urination, and feeling tired.
Increases cardiac output Increases heart rate Increases ventilation rate Increases basal metabolic rate Potentiates the effects of catecholamines (i.e. increases sympathetic activity) Potentiates brain development Thickens endometrium in females Increases catabolism of proteins and carbohydrates
Sources: en.wikipedia.org
=== Pharmacokinetics === When administered orally in a 70:30 molar ratio, serdexmethylphenidate/dexmethylphenidate produces a dexmethylphenidate plasma concentration profile with a time to maximum concentration Tmax of approximately 2 hours and an mean terminal elimination half-life of 11.7 hours.
2000 – 2008 Member of the board of the Technical University of Denmark. 2000 – 2003 Member of the Academy of Technical Sciences, Denmark 2003 – 2004 President of the Academy of Technical Sciences, Denmark 2006 – 2012 Member of the board of Cellartis AB, Sweden 2012 – 2019 Member of the board of the University of Copenhagen (chairman from 2017 to 2020) 2014 - 2016 Chairman of the board, Steno Diabetes Center, Denmark 2018 - 2019 Board member, Symphogen A/S, Denmark 2020 - Member of the board of BB Biotech AG, Switzerland
Therefore, the development of devices facilitating the transition from samples at higher pressure and in condensed phase (solid or liquid) into a vacuum system has been essential to develop MS as a potent tool for identification and quantification of organic compounds like peptides. MS is now in very common use in analytical laboratories that study physical, chemical, or biological properties of a great variety of compounds. Among the many different kinds of mass analyzers, the ones that find application in LC–MS systems are the quadrupole, time-of-flight (TOF), ion traps, and hybrid quadrupole-TOF (QTOF) analyzers.
During the 2010s, the Moroccan mafia was widely talked about in Dutch and Belgian politics. After the assassination of Derk Wiersum, a lawyer with information about Ridouan Taghi, Geert Wilders expressed his discontent in the Dutch parliament.
Sources: en.wikipedia.org
There is also significant doubt about whether β-arrestin is truly responsible for the side effects of opioids, and positive results suggesting G-protein activation may still produce constipation, respiratory depression, and tolerance. In summary, mitragynine pseudoindoxyl may still have a better therapeutic window compared to other full agonists, including other putatively biased G-protein agonists, but more research is needed to quantify this effect, particularly in humans, and to elucidate the cause. Cryo-EM structures of the μOR-Gi1 complex with mitragynine pseudoindoxyl and lofentanil (one of the most potent opioids) revealed that the two ligands engage distinct subpockets, and molecular dynamics simulations showed additional differences in the binding site that promote distinct active-state conformations on the intracellular side of the receptor where G proteins and β-arrestins bind. Importantly, studies have shown that oxidative metabolism is capable of transforming mitragynine (the main alkaloid in kratom) into mitragynine pseudoindoxyl in two steps, which is likely to influence kratom's complex pharmacological effects.
=== Generic forms === Generic forms of oral selegiline are available in the United States. However, generic forms of the orally disintegrating tablet and the transdermal patch are not available in this country. The latter formulations of selegiline are very expensive, and this can be prohibitive to their use. There has been poor insurance coverage of the transdermal patch form for depression, with insurance companies often requiring patients to first fail to respond to one or two other antidepressants and to be responsible for larger copayments. It is expected that generics of the transdermal patch will become available at some point in the future.
=== Endocrine disruption === LeBlanc's research in the field of toxicology, particularly centered on endocrine disruption, has contributed to the understanding of the impact of environmental contaminants on human and wildlife health. He investigated the impacts of endocrine-disrupting chemicals on mammals, fishes, reptiles, and invertebrates. He identified the suite of nuclear receptors in the crustacean, Daphnia pulex, and functionally characterized several of these receptors. He deciphered the neuro-endocrine signaling pathway responsible for sex determination in some crustaceans, including the discovery of the hormone responsible for sex determination, methyl farnesoate, and its receptor protein. He also demonstrated that some insecticides can mimic the action of methyl farnesoate in daphnids resulting in altered sex ratios of offspring. In 2005, LeBlanc created a mathematical model that integrated concentration addition, response addition, and toxicokinetic interactions to enable the assessment of the toxicity of chemical mixtures. He demonstrated the utility of this model by assessing the joint toxicity of 9 chemicals commonly found in surface waters in the US. This model has been used by regulatory agencies and has been recommended by the National Research Council in the assessment of risks to endangered and threatened species from exposure to pesticide mixtures.
In the Philippines, the first Mister Donut store opened in 1982 in Manila and has become the country's second largest doughnut chain, with Dunkin' Donuts as its main competitor. In 1995, the Ramcar Group took over the Philippine franchise of Mister Donut through its subsidiary, Food Fest, Inc. In 1997, Mister Donut helped finance the country's first ever feature-length animated film, Adarna: The Mythical Bird. Of its 1,800 outlets, the majority are stalls, often located inside shopping malls, while 200 are full-scale stores. Mister Donut products are also sold in 7-Eleven stores and KFC restaurants, the latter also franchised locally by Ramcar. Some locations sell coffee, but they mostly focus on doughnuts, including pasalubong, gifts by visitors to friends and family. The doughnuts sold are adjusted to suit the local market, with smaller sizes, therefore cheaper, and different flavors.
=== Treatment === An antidote has been developed by the British Armed Forces, although as of 2006, it has not yet been tested on humans. As of 2005, another antidote developed by the US military has been shown to be safe and effective in lab mice injected with antibody-rich blood mixed with ricin, and has had some human testing. Monoclonal antibodies are under scientific investigation as a possible treatment for ricin poisoning. Symptomatic and supportive treatments are available for ricin poisoning. Existing treatments emphasize minimizing the effects of the poison. Possible treatments include intravenous fluids or electrolytes, airway management, assisted ventilation, or giving medications to remedy seizures and low blood pressure. If the ricin has been ingested recently, the stomach can be flushed by ingesting activated charcoal or by performing gastric lavage. Survivors often develop long-term organ damage.
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.